Biotechnological preparations as a means of improving the safety of pharmacotherapy: state of the art and prospects of development

Biotechnological preparations as a means of improving the safety of pharmacotherapy: state of the art and prospects of development

Development and improvement of biotechnological drugs currently more relevant than ever. Drugs obtained by means of biotechnology, have a number of positive qualities. Biotechnology allows you to create such products, which are currently impossible to synthesize by chemical means, in addition, the p...

Full description

Bibliographic Details
Main Authors:	A. A. Lidzhieva, E. A. Smolyarchuk, A. E. Kokorina, V. V. Smirnov, E. A. Egorenkov
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2018-02-01
Series:	Биопрепараты: Профилактика, диагностика, лечение
Subjects:	биосимиляры биотехнологические препараты биотехнология инсулин соматотропин антибиотики интерферон моноклональные антитела ферменты biosimilar biotech drugs biotechnology insulin somatotropin antibiotics interferon monoclonal antibodies enzymes
Online Access:	https://www.biopreparations.ru/jour/article/view/57

Similar Items

RETRACTED: Biosimilars - advantages and prospects
by: A. A. Lidzhiyeva, et al.
Published: (2018-02-01)

Preparations of next generation monoclonal antibodies (issues and prospects)
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01)

Global Market of Monoclonal Antibodies: Sales, Prices, Demand
by: D. A. Uvarov
Published: (2021-04-01)

Systemic characteristic of safety profile of monoclonal antibodies used in rheumatology practice
by: A. V. Philippova, et al.
Published: (2019-10-01)

NEW DIRECTIONS IN ATHEROSCLEROSIS PHARMACOTHERAPY
by: S. V. Dutova, et al.
Published: (2017-12-01)

BIOSIMILARS, PRODUCED USING THE RECOMBINANT DNA TECHNOLOGY
by: Z. I. Avdeeva, et al.
Published: (2019-02-01)

Immunogenicity induced by biologicals in the treatment of psoriasis and psoriatic arthritis: View of the problem
by: T. V. Korotaeva
Published: (2016-01-01)

Assessment of biotechnological products specific activity
by: N. A. Alpatova, et al.
Published: (2018-02-01)

Producing and prospects for the use of bispecific antibodies for the treatment of cancer
by: S. E. Sedykh, et al.
Published: (2019-01-01)

BIOTECHNOLOGICAL PROCESSING OF COLLAGEN-CONTAINING RAW MATERIALS
by: G. . Zhumanova, et al.
Published: (2021-01-01)

DETERMINATION OF POLYSORBATE IN BIOTECH DRUGS
by: V. I. Grokhovskiy, et al.
Published: (2019-01-01)

Direct antiviral drugs and blocking monoclonal antibodies as the basis of etiotropic therapy of a novel coronavirus infection
by: V. B. Musatov
Published: (2022-10-01)

RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES
by: V. I. Chernov, et al.
Published: (2016-07-01)

“CAMEL” ANTIBODIES: FEATURES OF THEIR STRUCTURE, PREPARATION AND APPLICATION
by: Alexey Alekseevich Andreev, et al.
Published: (2020-06-01)

NEW MONOCLONAL ANTIBODY FOR TUMOR-ASSOCIATED PROTEIN PMEPA1 DETECTION
by: V. V. Volkomorov, et al.
Published: (2016-02-01)

New Monoclonal Antibodies for the Diagnosis of Influenza and other Acute Respiratory Viral Infections
by: A. A. Sominina, et al.
Published: (2015-10-01)

Modern biological/biotechnological medicinal products. Topical issues and prospects for development
by: Yu. V. Olefir, et al.
Published: (2018-02-01)

Safety issues of monoclonal antibodies used in rheumatology
by: A. V. Philippova, et al.
Published: (2020-01-01)

Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma
by: N. B. Abramenko, et al.
Published: (2019-09-01)

Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system
by: A. Yu Kulikov, et al.
Published: (2022-06-01)

DEVELOPMENT AND VALIDATION OF IMMUNOASSAY FOR IMMUNOGENICITY OF INTERFERON-ALPHA 2A DRUGS
by: E. V. Mityushova, et al.
Published: (2019-01-01)

Experimental and clinical approaches to a radioimmunotherapy in o
by: E. V. Abakushina, et al.
Published: (2016-02-01)

Monoclonal antibodies against Mycobacterium tuberculosis, detecting the antigen in urine of the pulmonary tuberculosis patients
by: A. V. Onyan, et al.
Published: (2016-02-01)

Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
by: Irina Mikhailovna Marusenko
Published: (2013-12-01)

Immunology and prospects of immunotherapy against malignant gliomas: humoral immunity
by: S. A. Kulyova, et al.
Published: (2021-12-01)

Rational sequence of monoclonal antibodies in the treatment of non-resectable head and neck squamous cell carcinoma
by: L. V. Bolotina, et al.
Published: (2022-04-01)

Focal segmental glomerulosclerosis: current status of the problem
by: I. T. Murkamilov, et al.
Published: (2020-01-01)

International nonproprietary names for biological and biotechnological drugs
by: V. V. Dudchenko, et al.
Published: (2018-02-01)

The Conditions of and Requirements for the Formation of Clusters in Biotechnology
by: Dávid Domonkos
Published: (2011-06-01)

Biotechnological clusters: background and development trends
by: A. S. Glazkova
Published: (2020-02-01)

Diagnosis of Bactec samples by immunoglobulins of mouse hyperimmune sera obtained against modified antigens of the cell wall of Mycobacterium tuberculosis
by: I. V. Kozlova, et al.
Published: (2019-11-01)

Pharmacokinetic properties of the preparations of protein origin
by: A. A. Soldatov, et al.
Published: (2018-02-01)

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
by: S. K. Zyryanov, et al.
Published: (2023-07-01)

The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01)

MODERN ONCO DRUG FOR INTERNAL USE
by: O. L. Orlova, et al.
Published: (2018-11-01)

QUANTITATIVE DETERMINATION OF HOST CELL PROTEINS (CHO) BY THE METHOD OF ENZYME IMMUNOASSAY IN THE PROTEIN ADALIMUMAB
by: P. M. Isaykina, et al.
Published: (2019-01-01)

Improving the treatment of the novel coronavirus infection (COVID-19) in children at risk for the development of severe disease with the use of virus-neutralizing monoclonal antibodies
by: A. S. Tokarev, et al.
Published: (2022-08-01)

Theoretical justification, practice and prospects of applied biotechnology in agronomy
by: S A Kornatsky, et al.
Published: (2012-09-01)

Khronicheskiy B-kletochnyy limfoleykoz: faktory prognoza pri lechenii fludarabinom i khlorambutsilom
by: E A Nikitin
Published: (2006-12-01)

Collagenases in medical practice: modern collagenase-based preparations and prospects for their improvement
by: A. V. Mayorova, et al.
Published: (2019-12-01)